Skip to main content

Peer Review reports

From: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

Original Submission
21 Nov 2020 Submitted Original manuscript
20 Jan 2021 Reviewed Reviewer Report
8 Feb 2021 Reviewed Reviewer Report
17 Feb 2021 Author responded Author comments - Mark G Anderson
Resubmission - Version 2
17 Feb 2021 Submitted Manuscript version 2
2 Mar 2021 Reviewed Reviewer Report
10 Mar 2021 Reviewed Reviewer Report
22 Mar 2021 Author responded Author comments - Mark G Anderson
Resubmission - Version 3
22 Mar 2021 Submitted Manuscript version 3
1 Apr 2021 Reviewed Reviewer Report
7 Apr 2021 Author responded Author comments - Mark G Anderson
Resubmission - Version 4
7 Apr 2021 Submitted Manuscript version 4
15 Apr 2021 Author responded Author comments - Mark G Anderson
Resubmission - Version 5
15 Apr 2021 Submitted Manuscript version 5
10 May 2021 Author responded Author comments - Mark G Anderson
Resubmission - Version 6
10 May 2021 Submitted Manuscript version 6
Publishing
25 May 2021 Editorially accepted
9 Jun 2021 Article published 10.1186/s12885-021-08403-5

You can find further information about peer review here.

Back to article page